Matthias founded Augmenticon with Dr. Christian Schmidt in June 2019. He also founded Arion Radiopharma Consulting in 2018 offering tailored solutions for radiopharmaceuticals development to pharma partners, investors, and academic institutions. Prior to starting this new enterprise, he co-founded Piramal Imaging and headed the chemical research & development, manufacturing and control (CMC) departments.
Prior to Piramal Imaging, Dr. Friebe served as VP of Radiochemistry Research, Diagnostic Research at Bayer HealthCare. He has been contributing to the field of radiotherapy, SPECT- and PET-probe development for more than 18 years.
He studied Chemistry at the Technical University Dresden and received his PhD (Chemistry, Radiopharmaceutical Chemistry) at the Research Center Dresden-Rossendorf/Technical University Dresden. He held various positions at the Swiss Federal Institute of Technology (Dept. of Biopharmacy), Zurich, Switzerland and Harvard Medical School (Dept. of Radiology), Boston, MA, U.S.A. prior to joining Schering AG / Bayer HealthCare.
He started his career 1999 in the pharmaceutical industry where he worked as a manager in solid dosage production at the Takeda plant in Oranienburg. Later he joined a European affiliate of Eli Lilly Co. where he managed a lab and several projects in late stage pharmaceutical development of solid and liquid dosage forms.
With his next move in 2007 to NOXXON Pharma he switched to early stage development of Aptamers where he held two roles in parallel: CMC manager and Head of QA. In 2013 Christian changed to the radiopharmaceutical industry and joined Life Molecular Imaging (fka. Piramal Imaging). Here, he is responsible globally for the manufacturing of the proprietary ß-amyloid PET tracer Neuraceq. In this role, he has been involved in multiple IT projects to design, setup and validate solutions for management of production, quality control, and quality management information.
Dr. Christian Schmidt studied pharmacy in Hamburg, Germany, where he graduated in 1995. He received his Ph.D. in 1999 from the University of Kiel, Germany, where he focused on production of pellets by extrusion/ spheronization.
Mr. Gause joined AUGMENTICON in June 2020 and takes care of developing AUGMENTICON’s corporate and business strategy and implementation plans. In this context, he will oversee and facilitate related funding rounds, investment and partnering projects of the company with a particular attention to the fast-growing Asia/Pacific region.
During the past 30 years, Mr. Gause held various executive positions in the pharmaceutical industry, both in Europe and in the APAC region. At this stage, he holds positions as the Managing Director of BGM Associates GmbH, and as the Chairmen of the Board of Medicinisto AG.